^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anaplastic Astrocytoma

    Related cancers:
    2d
    Expanding the molecular grading criteria in IDH-mutant astrocytoma. (PubMed, Neuro Oncol)
    The presence of CDK4, CCND2, PDGFRA, PIK3R1, MYCN, and EGFR alterations result in an intermediate patient survival in IDH-mutant astrocytoma. Adding these molecular alterations should be considered in future diagnostic classification systems to improve stratification of high-risk patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CCND2 (Cyclin D2)
    |
    EGFR mutation • PIK3CA mutation • EGFR amplification • CDKN2A deletion • MYCN amplification • PDGFRA mutation
    6d
    RagC and Map4K3 deficiency in high-grade gliomas drives proliferation and modulates mTORC1-dependent cellular functions. (PubMed, J Neuropathol Exp Neurol)
    In contrast, RagC-deficient U87 cells showed increased senescence but no autophagy induction. These data show that losses of RagC and Map4K3 in malignant gliomas have proliferation-inducing effects and differentially modulate key mTOR signaling-dependent cellular mechanisms.
    Journal
    |
    TFEB (Transcription Factor EB 2) • RRAGD (Ras related GTP binding)
    14d
    Clinical and genetic determinants of glioblastoma survival: a retrospective study. (PubMed, Front Mol Neurosci)
    A significant finding was the strong association between extent of resection, tumor proximity to the ventricular system and survival: patients with tumors closer to the ventricles had significantly shorter survival, highlighting the critical role of spatial tumor characteristics in glioblastoma outcomes. These results suggest that integrating clinical, genetic and spatial tumor data into personalized treatment approaches could improve prognosis.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    TP53 mutation • EGFR mutation
    18d
    Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (clinicaltrials.gov)
    P1/2, N=33, Not yet recruiting, Mayo Clinic
    New P1/2 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    Zynyz (retifanlimab-dlwr)
    18d
    Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion (clinicaltrials.gov)
    P1, N=15, Recruiting, Nationwide Children's Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    carboplatin • Lorbrena (lorlatinib) • cyclophosphamide
    21d
    UNITED-4: UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4 (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Sunnybrook Health Sciences Centre
    New trial
    |
    IDH wild-type
    22d
    High-grade gliomas and Lynch syndrome: A retrospective descriptive study with a literature review. (PubMed, Neurooncol Pract)
    We propose with a review of case in the literature an algorithm for investigating LS upon discovering a GBM. These exploratory results need to be confirmed by a larger cohort.
    Retrospective data • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • PTEN mutation
    1m
    Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse (clinicaltrials.gov)
    P2, N=19, Terminated, Exelixis | Completed --> Terminated; Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed.
    Trial termination
    |
    Cabometyx (cabozantinib tablet)
    1m
    A Case of IDH-Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant. (PubMed, Neuropathology)
    He received adjuvant concurrent radiation and temozolomide...We present a case of IDH-mutant astrocytoma with a somewhat atypical molecular presentation, including a previously uncharacterized IDH2 mutation, retained ATRX expression, and lack of MGMT promoter hypermethylation. Though it has not been biochemically or functionally validated, tumor methylation profiling is supportive of this previously uncharacterized IDH2 variant as tumorigenic.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ATRX (ATRX Chromatin Remodeler)
    |
    IDH2 mutation • IDH1 R132 • IDH2 R172
    |
    temozolomide
    1m
    A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression (clinicaltrials.gov)
    P1/2, N=68, Not yet recruiting, Lantern Pharma Inc.
    New P1/2 trial
    |
    IDH wild-type
    |
    hydroxyureamethylacylfulvene (STAR-001)
    1m
    Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov)
    P1/2, N=53, Terminated, National Cancer Institute (NCI) | Phase classification: P2 --> P1/2 | Completed --> Terminated; Unable to supply investigational agent, Zotiraciclib (TG02).
    Phase classification • Trial termination
    |
    TP53 (Tumor protein P53) • ATRX (ATRX Chromatin Remodeler)
    |
    temozolomide • zotiraciclib (TG02)
    1m
    The expression pattern and prognostic relevance of p120-catenin, COL4A2 and SOX10 in glioma. (PubMed, Front Oncol)
    In contrast, COL4A2 and SOX10 appear to act as tumor suppressors in glioma pathophysiology. SOX10 may additionally be a valuable prognostic marker in female GBM patients.
    Journal
    |
    SOX10 (SRY-Box 10) • CTNND1 (Catenin Delta 1)
    |
    IDH wild-type